Feature | February 10, 2014

Inflammation Testing May Predict Cardiac Risk in Corporate Wellness Programs

February 10, 2014 — Traditional fingerstick screening for glucose and lipids is proving inadequate when identifying near-term cardiovascular risk in employed populations, according to Jake Orville, CEO of Cleveland HeartLab (CHL). This position is supported by data from the American Heart Association. AHA reported 50 percent of all heart attacks and strokes occur in individuals with normal cholesterol and — for approximately 30 percent of patients with cardiovascular disease — their first sign of disease is death.
 
Orville is scheduled to present "The Role of Inflammation Testing in Corporate Wellness Programs" at the 2014 Health & Wellness Congress, Feb. 27-28. The conference, held at the Monte Carlo Resort and Casino in Las Vegas, will bring together leading corporate wellness experts to discuss emerging trends and strategies that promote well-being at the worksite.
 
"Inflammation testing provides reassurance on another important level," Orville said. "In addition to detecting employees with possible hidden risk, we are also able to provide positive feedback for those employees who are already leading healthy lifestyles. Knowing that their health habits are decreasing the inflammation in their blood vessels and their risk of an event can be a powerful incentive for people to stick with positive lifestyle changes."
 
Cleveland HeartLab is a provider of onsite testing for corporate wellness programs. A clinical laboratory and cardiovascular disease management provider, CHL offers a multi-marker approach — adding inflammation-specific blood tests to the traditional screening panel — to identify employees may go undetected. CHL's inflammatory biomarkers deliver insight into cardiovascular disease risk such as "vulnerable plaque" that may rupture into the vessel and block blood flow, leading to heart attack or stroke.
 
Orville will present both the science of inflammation testing and the results of corporate wellness programs that have adopted inflammation testing for risk stratification and targeted intervention. With new mandates from the Affordable Care Act for companies to provide screening programs to employees, obtaining the greatest efficacy as well as return on investment becomes paramount.
 
For more information: www.clevelandheartlab.com

Related Content

Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Corus CAD genetic test is a simple, noninvasive blood test that is clinically available for the assessment of obstructive coronary artery disease.

The Corus CAD genetic test is a simple, noninvasive blood test that is clinically available for the assessme

Feature | Genetic Testing| December 13, 2017 | Andrew Waxler, M.D., FACC
The diagnosis and management of cardiovascular disease has long followed a familiar approach.
VitalConnect Secures Fifth FDA Clearance for Patient Monitoring Device
Technology | Wearable Sensors| December 12, 2017
VitalConnect Inc. announced its fifth 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for the...
CorInnova Awarded 2017 InnoSTARS Prize for EpicHeart Soft Robotic Heart Assist Device
News | Artificial Heart| December 11, 2017
CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science competition for its...
ECG Study of NBA Players Shows Need for Sport-Specific Normative Data and Guidelines
News | ECG| December 08, 2017
Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings...
New Study Suggests Protein Could Protect Against Coronary Artery Disease

Patients with no obstructed blood flow in the coronary arteries had higher levels of CXCL5 (blue) compared to patients with moderate levels (green) or lower levels (yellow) of CXCL5, who had increased severity of coronary obstructions (indicated by the arrows). Credit: Schisler lab

News | Cardiac Diagnostics| December 07, 2017
December 7, 2017 — The buildup of plaque in the heart’s arteries is an unfortunate part of aging.
Edwards Acquires Harpoon Medical
News | Heart Valve Technology| December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Robocath Receives $1.5 Million in Capital for Advancement of R-One Robotic System
News | Robotic Systems| December 06, 2017
December 6, 2017 — French company Robocath, which designs and develops...
New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

Feature | December 06, 2017 | Dave Fornell
Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magaz
E-cigarettes Most Likely to be Used by Alcohol Drinkers and Former Cigarette Smokers, at American Heart Association (AHA), #AHA2017.
News | Cardiac Diagnostics| December 06, 2017
December 6, 2017 — Electronic cigarettes are more frequently used by people who recently quit smoking and alcohol dri
Overlay Init